Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris reports encouraging cancer trial results
These are assumed to be the first in-vivo data showing that SIRT1 overexpression can suppress tumor formation and growth. These data are the work of Sirtris scientific advisory
These are assumed to be the first in-vivo data showing that SIRT1 overexpression can suppress tumor formation and growth. These data are the work of Sirtris scientific advisory
The recent milestone payment was triggered by J&JPRD’s selection of a compound targeting the Cathepsin S enzyme as a development candidate. Under the terms of the collaboration agreement,
Under the terms of the agreement, CJ has purchased $2.5 million worth of Neuralstem stock at $4.063 per share. The terms of the license will be negotiated after
This trial is part of the company’s comprehensive development program in NHL, which represents a significant growth opportunity for Velcade. The primary endpoint of the open-label trial is
Under the terms of the agreement, ANP will receive an initial $2 million up-front payment. ANP also has the potential to receive payments related to the continued clinical
This agreement authorizes Siemens Healthcare to share the basic intellectual property of Prowess’s patented Direct Aperture Optimization (DAO) planning software, allowing Siemens to incorporate Prowess’s software into the
Under the terms of the agreement, Pfizer will make a cash tender offer for all issued and outstanding shares of Encysive for $2.35 per share, representing an equity
The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver
In the proposed PI changes, company is seeking the inclusion of six-year overall survival and five-year disease free survival data in Stage III colon cancer patients treated with
Under the terms of this licensing agreement, Sirion will have the rights to manufacture, sell and distribute norketotifen for ocular use either alone or in combination with other